Daily Market Reports | Apr 16 2026
This story features A2 MILK COMPANY LIMITED, and other companies.
For more info SHARE ANALYSIS: A2M
The company is included in ASX100, ASX200, ASX300 and ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
A2M ASK AUC CTM CU6 CWY DUR EML EMR FBU GHM (2) IOD LIC MHJ MM1 MSB OMA PYC QAN RMD STM TLX XRO
A2M A2 MILK COMPANY LIMITED
Dairy – Overnight Price: $7.71
Jarden rates ((A2M)) as Underweight (4) –
Jarden maintains its Underweight rating on a2 Milk Co and lowers the price target to NZ$9.20 from NZ$9.40 following a profit warning linked to supply chain disruptions.
The broker observes production backlogs, additional testing requirements for China and English-label products, and rising air freight costs stemming from the Middle East conflict are impacting near-term performance.
FY26 revenue guidance has been revised to low-to-mid double-digit growth, while EBITDA margins are forecast to contract to 14-14.5%.
Although brand momentum remains strong, the broker suggests the time and cost required to rebalance supply could extend beyond management’s expectations.
Financial forecasts have been updated to reflect these headwinds, with earnings per share estimates reduced by -13% for FY26 and -9% for FY27.
This report was published on April 13, 2026.
Current Price is $7.71. Target price not assessed.
Current consensus price target is $9.03, suggesting upside of 18.0%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 19.45 cents and EPS of 24.85 cents.
At the last closing share price the estimated dividend yield is 2.52%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 31.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.3, implying annual growth of N/A.
Current consensus DPS estimate is 17.9, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 31.5.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 60.39 cents and EPS of 29.53 cents.
At the last closing share price the estimated dividend yield is 7.83%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 26.11.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 29.0, implying annual growth of 19.3%.
Current consensus DPS estimate is 43.9, implying a prospective dividend yield of 5.7%.
Current consensus EPS estimate suggests the PER is 26.4.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ASK ABACUS STORAGE KING
REITs – Overnight Price: $1.36
Moelis rates ((ASK)) as Upgrade to Buy from Hold (1) –
Moelis upgrades Abacus Storage King to Buy from Hold with an unchanged $1.59 target price.
The broker observes the current share price appears attractive following a recent sell-off, offering an implied cap rate of 6.4%.
Earnings estimates were slightly adjusted to account for a higher cost of debt, though dividend forecasts remain unchanged across the forecast period.
Yield is expected to grow as the company delivers on its $620m development pipeline and stabilises previously completed assets.
Commentary suggests potential internalisation of management functions could lead to corporate cost savings, though these are not yet incorporated into estimates.
This report was published on April 15, 2026.
Target price is $1.59 Current Price is $1.36 Difference: $0.225
If ASK meets the Moelis target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $1.55, suggesting upside of 13.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 6.20 cents and EPS of 6.30 cents.
At the last closing share price the estimated dividend yield is 4.54%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.8, implying annual growth of -69.1%.
Current consensus DPS estimate is 6.2, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 20.1.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 6.20 cents and EPS of 6.40 cents.
At the last closing share price the estimated dividend yield is 4.54%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.1, implying annual growth of 4.4%.
Current consensus DPS estimate is 6.3, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 19.3.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AUC AUSGOLD LIMITED
Gold & Silver – Overnight Price: $1.03
Canaccord Genuity rates ((AUC)) as Speculative Buy (1) –
Ausgold has reported positive results from its expanded 54,000-metre drilling program at the 100%-owned Katanning Gold Project in Western Australia.
The program, which now utilises five drill rigs, has successfully completed over 46,000 metres of extensional and infill drilling to date.
High-grade intercepts from the Jinkas-White Dam deposit have reconciled above current resource grades, increasing confidence in converting resources to reserves and de-risking early production cash flows.
Commentary highlights strategically significant results also identified down-plunge repetitions of the White Dam lode, potentially expanding the overall resource inventory beyond the current 2.44Moz estimate.
The broker maintains its Speculative Buy rating and $3.45 price target as further results remain pending from the ongoing campaign.
This report was published on April 14, 2026.
Target price is $3.45 Current Price is $1.03 Difference: $2.415
If AUC meets the Canaccord Genuity target it will return approximately 233% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 3.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 34.50.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 51.75.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CTM CENTAURUS METALS LIMITED
Nickel – Overnight Price: $0.65
Canaccord Genuity rates ((CTM)) as Speculative Buy (1) –
Centaurus Metals has updated the market on financing progress for its Jaguar Nickel Sulphide Project in northern Brazil, following strong interest from international financiers.
The company has received engagement from ten major resource financiers, with non-binding proposals totalling up to US$320m.
A preferred financing partner is expected to be appointed in the September quarter of 2026, aligning with the targeted final investment decision.
Construction of the project could commence in early 2027 following a 24-month build period.
Earnings and dividend forecast changes were not referenced as the update focuses on the formal project financing process.
This report was published on April 13, 2026.
Target price is $0.85 Current Price is $0.65 Difference: $0.205
If CTM meets the Canaccord Genuity target it will return approximately 32% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CU6 CLARITY PHARMACEUTICALS LIMITED
Medical Equipment & Devices – Overnight Price: $3.14
Canaccord Genuity rates ((CU6)) as Buy (1) –
The analysts at Canaccord Genuity now see potential for prostate-specific membrane antigen positron emission tomography (PSMA PET) beyond simply selecting patients for radioligand therapies (RLTs).
The broker explains a European Urology paper has provided randomised evidence that PSMA PET/CT is a strong prognostic biomarker for overall survival in patients with metastatic castrate-resistant prostate cancer.
Canaccord suggests ‘treatment monitoring’ as a new potential indication could increase annualised PSMA PET total addressable market volumes in the US by more than 10%.
The analysts expect to see earlier switching to RLTs such as Clarity Pharmaceuticals’ TLX591 67Cu-SARbisPSMA, if approved.
Unchanged Buy rating and $8.41 target.
This report was published on April 13, 2026.
Target price is $8.41 Current Price is $3.14 Difference: $5.27
If CU6 meets the Canaccord Genuity target it will return approximately 168% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CWY CLEANAWAY WASTE MANAGEMENT LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $2.28
Jarden rates ((CWY)) as Buy (1) –
Jarden maintains its Buy rating on Cleanaway Waste Management with an unchanged price target of $3.10 after the company downgraded its full-year EBIT guidance.
The broker notes rising diesel costs and activity disruptions caused a -$20m impact, resulting in a tighter margin outlook for the second half of the year.
Core EPS forecasts have been reduced by -9.2% for FY26, as the business navigates a timing disconnect between immediate fuel price hikes and subsequent contract repricing.
While earnings and dividend forecasts were lowered to reflect higher supplier costs, net finance cost estimates remain unchanged at -$155m for the current year as the broker anticipates near-term risks are largely dimensioned.
Commentary suggests investors now look toward the upcoming strategy day for clarity regarding free cash flow generation and capital intensity.
This report was published on April 14, 2026.
Target price is $3.10 Current Price is $2.28 Difference: $0.82
If CWY meets the Jarden target it will return approximately 36% (excluding dividends, fees and charges).
Current consensus price target is $3.05, suggesting upside of 33.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 5.50 cents and EPS of 9.70 cents.
At the last closing share price the estimated dividend yield is 2.41%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.51.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 10.4, implying annual growth of 47.9%.
Current consensus DPS estimate is 6.9, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 21.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 8.30 cents and EPS of 12.10 cents.
At the last closing share price the estimated dividend yield is 3.64%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.84.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 12.4, implying annual growth of 19.2%.
Current consensus DPS estimate is 8.3, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 18.4.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
DUR DURATEC LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $2.84
Moelis rates ((DUR)) as Buy (1) –
Moelis maintains its Buy rating on Duratec and increases the target price to $3.08 following a major contract award and strategic acquisition.
The company secured a $281m contract for infrastructure upgrades at HMAS Stirling through its joint venture to support future submarine capabilities.
Additionally, the acquisition of Pacific Welding Australia is seen as strengthening its self-perform capability and presence in the Hunter Region.
Earnings estimates for FY27 and FY28 have been upgraded by 7% and 11% respectively to reflect both events.
Moelis views continued contract conversions in the defence and energy sectors as significant near-term catalysts for the stock.
This report was published on April 15, 2026.
Target price is $3.08 Current Price is $2.84 Difference: $0.24
If DUR meets the Moelis target it will return approximately 8% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EML EML PAYMENTS LIMITED
Business & Consumer Credit – Overnight Price: $0.36
Canaccord Genuity rates ((EML)) as Buy (1) –
Canaccord Genuity maintains its Buy rating on EML Payments while lowering the price target to $1.60 from $1.75 following a reduction in management guidance, i.e. another old fashioned profit warning.
The broker observes FY26 underlying EBITDA guidance was lowered to $47m-$50m due to delays in new program launches and underperformance in Northern Hemisphere gifting programs.
Macroeconomic uncertainty and weakening consumer demand in Europe are expected to continue influencing results through the fourth quarter.
Despite near-term “bumps”, the broker remains positive on the medium-term growth trajectory given a successful pipeline build to over $105m since FY24.
Adjusted EBITDA forecasts have been updated to reflect management’s revised guidance and a more conservative outlook for FY27.
This report was published on April 13, 2026.
Target price is $1.60 Current Price is $0.36 Difference: $1.235
If EML meets the Canaccord Genuity target it will return approximately 338% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.04.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.84 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.34.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EMR EMERALD RESOURCES NL
Gold & Silver – Overnight Price: $6.37
Canaccord Genuity rates ((EMR)) as Buy (1) –
Canaccord Genuity maintains a Buy rating on Emerald Resources with an unchanged $8.20 price target following March quarter production at the Okvau mine.
The broker observes production was below expectations, although costs were better than forecast, supported by reduced reliance on diesel through grid power usage.
The broker notes achieving the low end of full-year guidance will require a strong final quarter.
Forecasts have been updated to reflect recent production trends.
This report was published on April 14, 2026.
Target price is $8.20 Current Price is $6.37 Difference: $1.83
If EMR meets the Canaccord Genuity target it will return approximately 29% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 41.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.54.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 12.00 cents and EPS of 64.00 cents.
At the last closing share price the estimated dividend yield is 1.88%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.95.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
FBU FLETCHER BUILDING LIMITED
Building Products & Services – Overnight Price: $2.48
Jarden rates ((FBU)) as Buy (1) –
Jarden upgrades its rating on Fletcher Building to Buy from Overweight and reduces the price target to NZ$4.16 from NZ$4.23.
The broker observes the company remains well-positioned against covenants despite modestly negative earnings headwinds from the recent fuel crisis.
House price growth expectations are maintained at 3% for 2026 and 2027, although Jarden argues downside risks persist amid weaker business confidence.
Commentary explains the upgrade reflects improved valuation upside following recent share price weakness.
Forecasts have been updated to reflect near-term earnings impacts and revised volume recovery assumptions.
This report was published on April 13, 2026.
Current Price is $2.48. Target price not assessed.
Current consensus price target is $2.76, suggesting upside of 12.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 10.61 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.37.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 12.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 20.4.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 16.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.76.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 16.4, implying annual growth of 36.7%.
Current consensus DPS estimate is 1.1, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 14.9.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GHM GOLDEN HORSE MINERALS LIMITED
Gold & Silver – Overnight Price: $0.46
Canaccord Genuity rates ((GHM)) as Speculative Buy (1) –
Canaccord Genuity notes Golden Horse Minerals continues to report encouraging exploration results from its Southern Cross operations in Western Australia, focusing on shallow, high-grade gold mineralisation at the Hopes Hill Project.
Initial scout drilling at Hopes Hill South successfully intersected significant near-surface gold, confirming a mineralised shear zone beneath historical workings and supporting the company’s geological model.
Across Hopes Hill Main and North, ongoing drilling continues to define scale and continuity, with mineralisation now extending along a 1.3km strike length.
The broker observes recent petrographic analysis confirms the gold is free-milling, supporting conventional processing and potentially strong recoveries.
Development studies are progressing alongside regional drilling at other prospects, with the broker maintaining a Speculative Buy rating as further assays remain pending.
This report was published on April 14, 2026.
Target price is $1.50 Current Price is $0.46 Difference: $1.04
If GHM meets the Canaccord Genuity target it will return approximately 226% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Shaw and Partners rates ((GHM)) as Buy (1) –
Shaw and Partners maintains its Buy recommendation and $1.50 price target for Golden Horse Minerals following standout exploration results at Hopes Hill South.
The broker observes shallow, high-grade intersections validate a large-scale shear-hosted system and reveal new growth opportunities near historic workings.
Among the observations made is continued strong results from Main and North areas highlight significant near-surface and depth upside across the broader Southern Cross project.
Drilling has confirmed a mineralised footprint exceeding 1.3km in strike with potential for further extensions. Financial forecasts have been updated to reflect higher anticipated exploration spend and updated share counts.
This report was published on April 15, 2026.
Target price is $1.50 Current Price is $0.46 Difference: $1.04
If GHM meets the Shaw and Partners target it will return approximately 226% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IOD IODM LIMITED
Cloud services – Overnight Price: $0.17
Shaw and Partners rates ((IOD)) as Buy (1) –
Shaw and Partners re-iterates its Buy rating on IODM and increases its price target to $0.29 from $0.23 following an expanded partnership in the US and renewed terms in the UK.
The broker observes the expanded partnership with TransferMate targets adding roughly 60 shared US university clients per year, which could be transformational for the group.
Growth in the UK is also expected to accelerate now that exclusivity has been removed, providing opportunities for new regional partners.
The broker forecasts a 50% revenue compound annual growth rate through FY29, supported by minimal incremental costs.
Forecasts have been updated to reflect higher anticipated cash flows and margins from the new commercial arrangements.
This report was published on April 14, 2026.
Target price is $0.29 Current Price is $0.17 Difference: $0.125
If IOD meets the Shaw and Partners target it will return approximately 76% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 55.00.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LIC LIFESTYLE COMMUNITIES LIMITED
Aged Care & Seniors – Overnight Price: $4.56
Canaccord Genuity rates ((LIC)) as Buy (1) –
Canaccord Genuity maintains its Buy rating on Lifestyle Communities but lowers the price target to $5.90 from $6.05 following a “solid” third-quarter update.
The broker observes the company remains on track to meet estimated full-year settlement of 230 new homes, supported by 190 settlements completed year-to-date.
Ongoing de-leveraging has seen net debt reduce to $296.4m, driven by a continued unwind of completed inventory.
However, the broker has tempered settlement expectations for FY27 to reflect consumer caution surrounding inflation and potential future interest rate increases.
Forecasts have been updated to include a -5% reduction to FY27 EBITDA estimate to account for these potential headwinds.
This report was published on April 15, 2026.
Target price is $5.90 Current Price is $4.56 Difference: $1.34
If LIC meets the Canaccord Genuity target it will return approximately 29% (excluding dividends, fees and charges).
Current consensus price target is $5.54, suggesting upside of 20.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 21.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.71.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 21.0.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 20.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.80.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 26.3, implying annual growth of 19.5%.
Current consensus DPS estimate is 4.5, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 17.5.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MHJ MICHAEL HILL INTERNATIONAL LIMITED
Luxury – Overnight Price: $0.38
Jarden rates ((MHJ)) as Overweight (2) –
Jarden maintains an Overweight rating on Michael Hill with a NZ$0.80 price target following a refinement of the retailer’s brand strategy.
The broker observes the company is consolidating its portfolio from five down to two core banners —Michael Hill and Bevilles— to simplify operations and resource allocation.
Recent trading showed positive same-store sales growth of 4.6%, supported by continued strength in Canada.
However, near-term earnings expectations have been reduced due to softer consumer conditions and margin pressure.
Management has outlined aspirational longer-term growth and margin targets, with commentary suggesting valuation is supported by the streamlined strategy despite near-term headwinds.
This report was published on April 14, 2026.
Target price is $0.80 Current Price is $0.38 Difference: $0.42
If MHJ meets the Jarden target it will return approximately 111% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 1.00 cents and EPS of 3.00 cents.
At the last closing share price the estimated dividend yield is 2.63%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.67.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 4.00 cents and EPS of 6.50 cents.
At the last closing share price the estimated dividend yield is 10.53%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.85.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MM1 MIDAS MINERALS LIMITED
Copper – Overnight Price: $0.78
Canaccord Genuity rates ((MM1)) as Speculative Buy (1) –
Canaccord Genuity maintains its Speculative Buy rating and $1.35 price target for Midas Minerals Ltd following the reported extension of high-grade copper-silver mineralisation at the Spaatzu prospect.
The broker observes a standout intercept approximately 300m west of the original discovery hole confirms the lateral continuity of the mineralised system.
Geological interpretation suggests mineralisation is structurally controlled, with higher-grade zones localised along specific fault or vent systems.
With two rigs active at the site, the broker anticipates further results will help define the scale of the emerging copper-silver system.
No updates have been made to financial forecasts as the company remains in the exploration phase without active production revenue.
This report was published on April 13, 2026.
Target price is $1.35 Current Price is $0.78 Difference: $0.57
If MM1 meets the Canaccord Genuity target it will return approximately 73% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MSB MESOBLAST LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $2.17
Canaccord Genuity rates ((MSB)) as Buy (1) –
Canaccord Genuity maintains its Buy rating on Mesoblast with an unchanged $3.23 price target following the biotech’s research and development day.
The broker observes management expects to double the current revenue run-rate for its lead product in the medium term.
High uptake is anticipated in the adult population if ongoing trials deliver positive results, the broker reports.
The report concludes regulatory and commercial strategy questions remain for other pipeline programs.
This report was published on April 14, 2026.
Target price is $3.23 Current Price is $2.17 Difference: $1.06
If MSB meets the Canaccord Genuity target it will return approximately 49% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
OMA OMEGA OIL & GAS LIMITED
Energy – Overnight Price: $0.83
Canaccord Genuity rates ((OMA)) as Speculative Buy (1) –
Canaccord Genuity maintains its Speculative Buy rating on Omega Oil & Gas and raises the price target to $1.30 from $0.85.
The broker believes the Queensland Premier’s recent visit to the Taroom Trough represents a key turning point in political support for onshore development.
Regulatory risks are fast evaporating, the report concludes, potentially leading to higher corporate activity near existing infrastructure.
Commentary highlights encouraging drilling results from nearby operators and Shell’s ongoing testing have exceeded expectations and suggest highly economic flow rates.
The company is scheduled to commence its own drilling campaign across the Canyon Project mid-year.
This report was published on April 14, 2026.
Target price is $1.30 Current Price is $0.83 Difference: $0.465
If OMA meets the Canaccord Genuity target it will return approximately 56% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 49.12.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 49.12.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PYC PYC THERAPEUTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $1.21
Canaccord Genuity rates ((PYC)) as Buy (1) –
Canaccord Genuity maintains its Buy rating on PYC Therapeutics while slightly adjusting the price target to $2.84 following a significant capital raise of $600.5m.
The broker observes the company is now sufficiently funded to progress its RNA asset pipeline across kidney, retinal, and neuro indications.
Particular interest remains focused on the kidney asset due to its elegant mechanism of action and well-defined orphan indication with a large eligible population.
Commentary suggests market attention is now shifting toward upcoming updates from the multiple ascending dose portion of clinical trials expected in mid-2026.
Financial forecasts have been updated to reflect the increased share count and revised research and development expenditure.
This report was published on April 15, 2026.
Target price is $2.84 Current Price is $1.21 Difference: $1.63
If PYC meets the Canaccord Genuity target it will return approximately 135% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 8.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 15.13.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 11.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 11.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
QAN QANTAS AIRWAYS LIMITED
Transportation & Logistics – Overnight Price: $9.09
Jarden rates ((QAN)) as Buy (1) –
Jarden maintains its Buy rating on Qantas Airways while lowering the price target to $11.25 from $12.70 following updated fuel cost guidance.
The airline increased its second-half fuel cost guidance to a range of -$3.1bn to -$3.3bn due to ongoing volatility following the Middle East conflict.
To offset these costs, the group has implemented higher revenue management targets and modestly reduced its capacity guidance for the remainder of the year.
Core EPS forecasts have been reduced by -24% for FY26 and FY27 to reflect a projected net fuel cost headwind of -$200m per month.
The broker believes the company is well-capitalised with the flexibility to manage through near-term volatility, despite the significant magnitude of the fuel price revisions
This report was published on April 15, 2026.
Target price is $11.25 Current Price is $9.09 Difference: $2.16
If QAN meets the Jarden target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $10.83, suggesting upside of 18.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 39.60 cents and EPS of 90.40 cents.
At the last closing share price the estimated dividend yield is 4.36%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 102.4, implying annual growth of -2.6%.
Current consensus DPS estimate is 39.2, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 8.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 39.00 cents and EPS of 95.00 cents.
At the last closing share price the estimated dividend yield is 4.29%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.57.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 113.9, implying annual growth of 11.2%.
Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 8.0.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RMD RESMED INC
Medical Equipment & Devices – Overnight Price: $32.70
Canaccord Genuity rates ((RMD)) as Buy (1) –
Canaccord Genuity maintains its Buy rating on ResMed with an unchanged $46.50 price target following news regarding a limited US market exemption for a competitor’s device (Philips).
The broker explains the development is not a signal of a full market return, as regulatory restrictions for Philips remain in place for the broader population.
A wider re-entry is not expected until later in 2026, which supports ResMed’s continued market position in the near term, in the broker’s view.
Focus shifts to upcoming third-quarter results scheduled for 1 May, with no updates made to annual financial forecasts.
This report was published on April 14, 2026.
Target price is $46.50 Current Price is $32.70 Difference: $13.8
If RMD meets the Canaccord Genuity target it will return approximately 42% (excluding dividends, fees and charges).
Current consensus price target is $46.66, suggesting upside of 45.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 36.85 cents and EPS of 166.37 cents.
At the last closing share price the estimated dividend yield is 1.13%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.66.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 155.0, implying annual growth of N/A.
Current consensus DPS estimate is 34.5, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 20.7.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 39.41 cents and EPS of 184.12 cents.
At the last closing share price the estimated dividend yield is 1.21%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.76.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 173.7, implying annual growth of 12.1%.
Current consensus DPS estimate is 38.5, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 18.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
STM SUNSTONE METALS LIMITED
Copper – Overnight Price: $0.35
Shaw and Partners rates ((STM)) as Buy (1) –
Shaw and Partners maintains a Buy rating and $2.10 price target on Sunstone Metals as early hits from the 2026 Bramaderos drill program confirm system scale.
The broker highlights mineralised intersections of 200m and 162m, which underscore the potential for substantial resource growth.
An imminent scoping study is expected to outline project economics and assist in assessing value relative to peers.
Ongoing partner discussions are currently taking place against a backdrop of record gold prices and high M&A activity in Ecuador.
Financial estimates have been updated to reflect the ramp-up in drilling activity and adjusted capital requirements.
This report was published on April 15, 2026.
Target price is $2.10 Current Price is $0.35 Difference: $1.75
If STM meets the Shaw and Partners target it will return approximately 500% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 29.17.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 38.89.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $14.80
Canaccord Genuity rates ((TLX)) as Buy (1) –
The analysts at Canaccord Genuity now see potential for prostate-specific membrane antigen positron emission tomography (PSMA PET) beyond simply selecting patients for radioligand therapies (RLTs).
The broker explains a European Urology paper has provided randomised evidence that PSMA PET/CT is a strong prognostic biomarker for overall survival in patients with metastatic castrate-resistant prostate cancer.
Canaccord highlights ‘treatment monitoring’ as a new potential indication could increase annualised PSMA PET total addressable market volumes in the US by more than 10%.
The analysts expect to see earlier switching to RLTs such as Telix Pharmaceuticals’ TLX591.
Unchanged Buy rating and $30 target.
This report was published on April 13, 2026.
Target price is $30.00 Current Price is $14.80 Difference: $15.2
If TLX meets the Canaccord Genuity target it will return approximately 103% (excluding dividends, fees and charges).
Current consensus price target is $25.84, suggesting upside of 72.5%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -2.7, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 36.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 41.3.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
XRO XERO LIMITED
Accountancy – Overnight Price: $75.10
Jarden rates ((XRO)) as Buy (1) –
Jarden maintains its Buy rating on Xero with a $120.00 price target, reduced from $150.00, following revisions to long-term forecasts and the inclusion of the Melio acquisition.
The broker expects revenue growth will remain strong, supported by contributions from Melio, although subscriber growth has softened in key markets.
Near-term earnings forecasts are modestly upgraded, supported by favourable currency movements.
Longer-term estimates have been reduced to reflect slower market penetration. The valuation reset is a result of the updated outlook.
This report was published on April 13, 2026.
Target price is $120.00 Current Price is $75.10 Difference: $44.9
If XRO meets the Jarden target it will return approximately 60% (excluding dividends, fees and charges).
Current consensus price target is $149.08, suggesting upside of 87.3%(ex-dividends)
The company’s fiscal year ends in March.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 141.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 53.19.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 105.7, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 75.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 138.29 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 54.31.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 105.6, implying annual growth of -0.1%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 75.4.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: A2M - A2 MILK COMPANY LIMITED
For more info SHARE ANALYSIS: ASK - ABACUS STORAGE KING
For more info SHARE ANALYSIS: AUC - AUSGOLD LIMITED
For more info SHARE ANALYSIS: CTM - CENTAURUS METALS LIMITED
For more info SHARE ANALYSIS: CU6 - CLARITY PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: CWY - CLEANAWAY WASTE MANAGEMENT LIMITED
For more info SHARE ANALYSIS: DUR - DURATEC LIMITED
For more info SHARE ANALYSIS: EML - EML PAYMENTS LIMITED
For more info SHARE ANALYSIS: EMR - EMERALD RESOURCES NL
For more info SHARE ANALYSIS: FBU - FLETCHER BUILDING LIMITED
For more info SHARE ANALYSIS: GHM - GOLDEN HORSE MINERALS LIMITED
For more info SHARE ANALYSIS: IOD - IODM LIMITED
For more info SHARE ANALYSIS: LIC - LIFESTYLE COMMUNITIES LIMITED
For more info SHARE ANALYSIS: MHJ - MICHAEL HILL INTERNATIONAL LIMITED
For more info SHARE ANALYSIS: MM1 - MIDAS MINERALS LIMITED
For more info SHARE ANALYSIS: MSB - MESOBLAST LIMITED
For more info SHARE ANALYSIS: OMA - OMEGA OIL & GAS LIMITED
For more info SHARE ANALYSIS: PYC - PYC THERAPEUTICS LIMITED
For more info SHARE ANALYSIS: QAN - QANTAS AIRWAYS LIMITED
For more info SHARE ANALYSIS: RMD - RESMED INC
For more info SHARE ANALYSIS: STM - SUNSTONE METALS LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: XRO - XERO LIMITED